Paridiprubart (EB05) showed positive Phase III results for ARDS treatment. The company is evaluating subgroup data for additional efficacy signals, and the US allocated USD 117 million to evaluate three novel therapeutics including Edesa's candidate.
Articles that tag EDSA but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
